Emily Wheeler is Director of Infectious Disease Policy at the Biotechnology Innovation Organization (BIO). Ms. Wheeler is responsible for working with member companies engaged in antimicrobial research, development, and commercialization, and leads BIO’s antimicrobial resistance (AMR) legislative and regulatory policy efforts. She is also the Director of the Working to Fight AMR public awareness campaign. Ms. Wheeler serves on the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) and is a member of the Stakeholder Group for the Global AMR R&D Hub. She represents the biotech sector as Board member on the AMR Industry Alliance (AMRIA) and is co-Chair of AMRIA’s Research and Science Working Group. Prior to joining BIO, Ms. Wheeler held a position as Associate Director at The Conafay Group, a life-sciences government relations firm that serves as coalition manager and Washington Counsel for the Antimicrobials Working Group (AWG). In this role Ms. Wheeler led AMR policy efforts for a coalition of small and mid-sized antimicrobials companies, and engaged with stakeholders representing health care providers, patients, public health, scientists, and industry. Ms. Wheeler has gained experience in health care policy and provision both domestically and internationally. She conducted fieldwork in Senegal, Rwanda and the Philippines focused on health care in several capacities: maternal and child health, nutrition, emergency relief for refugee populations, and monitoring and evaluation for a variety of programs. Additionally, she developed skills in project management and overall programmatic analysis through collaboration with local and international health and development experts. Ms. Wheeler is a Presidential Academic Scholar from the George Washington University and earned a bachelor’s degree in International Affairs with dual concentrations in Global Public Health and International Development.